Effectiveness and Safety of Rivaroxaban Versus Warfarin in Nonvalvular Atrial Fibrillation Patients with Severe Kidney Disease or Undergoing Hemodialysis.

Link to article at PubMed

Related Articles

Effectiveness and Safety of Rivaroxaban Versus Warfarin in Nonvalvular Atrial Fibrillation Patients with Severe Kidney Disease or Undergoing Hemodialysis.

Am J Med. 2019 May 02;:

Authors: Coleman CI, Kreutz R, Sood N, Bunz TJ, Eriksson D, Meinecke AK, Baker WL

Abstract
BACKGROUND: Nonvalvular atrial fibrillation patients with stage 4 or 5 chronic kidney disease or undergoing hemodialysis were excluded from phase III randomized trials of nonvitamin K antagonist oral anticoagulants (NOACs). We sought to evaluate the effectiveness and safety of rivaroxaban versus warfarin in nonvalvular atrial fibrillation patients with stage 4 or 5 chronic kidney disease or undergoing hemodialysis in routine practice.
METHODS: Using MarketScan data from 1/2012-12/2017, we identified oral anticoagulant (OAC)-naïve nonvalvular atrial fibrillation patients with stage 4 or 5 chronic kidney disease or undergoing hemodialysis and with ≥12-months of insurance coverage before OAC initiation. Differences in baseline covariates between the rivaroxaban and warfarin cohorts were adjusted using inverse probability-of-treatment weights based on propensity scores calculated using generalized boosted models and 10,000 regression trees (absolute standardized differences <0.1 achieved for all covariates after adjustment). Patients were followed until a stroke/systemic embolism or major bleeding event, OAC discontinuation/switch, insurance disenrollment or end of data availability. Hazard ratios (HRs) and 95% confidence intervals (CIs) comparing the OAC cohorts were calculated using Cox regression.
RESULTS: We identified 1896 rivaroxaban (38.7% received a dose <20mg/day) and 4848 warfarin users. Eighty-eight percent of included patients had stage 5 chronic kidney disease or were undergoing hemodialysis. Rivaroxaban did not significantly reduce stroke/systemic embolism (HR=0.55, 95%CI=0.27-1.10) or ischemic stroke (HR=0.67, 95%CI=0.30-1.50) alone, but was associated with a significant 32% (95%CI=1-53%) reduction in major bleeding risk versus warfarin.
CONCLUSION: Among nonvalvular atrial fibrillation patients with stage 4 or 5 chronic kidney disease or undergoing hemodialysis, rivaroxaban appears associated with significantly less major bleeding compared to warfarin.

PMID: 31054829 [PubMed - as supplied by publisher]

Leave a Reply

Your email address will not be published. Required fields are marked *